NCT02545465已完成不适用
Retrospective Chart Review of Patients With PAH or Inoperable/Persistent/Recurrent CTEPH Who Transition Their PH Treatment to Adempas
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Bayer
- 入组人数
- 125
- 主要终点
- Starting Dose
研究概览
简要总结
The aim of this study is to understand the treatment patterns in patients with Pulmonary Arterial Hypertension (PAH) or Chronic Thromboembolic Pulmonary Hypertension (CTEPH) during a switch of treatment to Adempas in real-life clinical practice.
In addition, this study will describe patient demographics and reason for switching
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Female and male adult patients diagnosed with PAH or inoperable/recurrent/persistent CTEPH who have been switched from a PH treatment (i.e. Endothelin Receptor Antagonist(ERAs), Phosphodiesterase-5 inhibitor(PDE5i) or Prostacyclin Analog (PCA) to Adempas
排除标准
- •Patients participating in an investigational program with interventions outside of routine clinical practice
- •Patients who have not switched their therapy from an Endothelin Receptor Antagonist (ERA) or Prostacyclin Analog (PCA) but received Adempas purely as an add-on therapy
研究组 & 干预措施
BAY63-2521
Patients who have been switched from a Pulmonary Hypertension treatment to Adempas
干预措施: Riociguat (Adempas, BAY63-2521) (Drug)
结局指标
主要结局
Starting Dose
时间窗: Up to a total of 8 weeks of titration period
Dose Increments
时间窗: Up to a total of 8 weeks of titration period
Final Dose
时间窗: Up to a total of 8 weeks of titration period
次要结局
未报告次要终点
研究者
相似试验
已完成
不适用
Retrospective Data Analysis of Data From the Zurich PH RegistryChronic Thromboembolic Pulmonary HypertensionPulmonary Artery HypertensionPulmonary HypertensionNCT03198910University of Zurich313
Unknown
不适用
Rehabilitation for Patients With Pulmonary Arterial HypertensionPulmonary Arterial HypertensionNCT00544726Rabin Medical Center45
撤回
不适用
Patient Reported Outcomes in Pulmonary Arterial HypertensionPulmonary Arterial HypertensionNCT01792622Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
已完成
不适用
Side Effects of Pulmonary Hypertension MedicationsPulmonary HypertensionNCT01571713Stanford University250
已完成
不适用
Pulmonary Arterial Hypertension in Patients With Direct-Acting Antiviral Medications for Hepatitis C Virus InfectionPulmonary Artery HypertensionChronic Hepatitis cNCT04094272Kantonsspital Olten49